GlassScriptPhysician profile
Wafa Akkad
NPI 1578739405
$3,634.11
in general payments reported to CMS, 2019-2025
33 companies · $971 in 2025
The $971 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $288 · 2021: $231 · 2022: $389 · 2023: $518 · 2024: $391 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.62 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $354.62 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $348.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $249.67 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $239.60 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $160.95 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Lilly USA, LLC | $147.36 | 2019-2025 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $118.26 | 2019-2021 | |
| Astellas Pharma US INC | $109.86 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.20 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $96.67 | 2019-2023 | Xarelto |
| Pfizer INC. | $77.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.07 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $44.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.49 | 2023-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.04 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $27.58 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $27.30 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.45 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $25.18 | 2021-2022 | |
| Circassia INC. | $24.74 | 2019-2020 | |
| Exact Sciences Corporation | $23.33 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $21.55 | 2025 | Gemtesa |
| Radius Health, INC. | $20.79 | 2024 | Tymlos |
| Corcept Therapeutics | $16.73 | 2025 | Korlym |
| Dexcom, INC. | $16.72 | 2023 | Dexcom G6 Transmitter |
| Shire North American Group INC | $15.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.11 | 2022 | |
| Alfasigma USA, INC. | $12.25 | 2020 | |
| Allergan, INC. | $11.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wafa Akkad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.